GB201513740D0 - Muscarinic agonist - Google Patents

Muscarinic agonist

Info

Publication number
GB201513740D0
GB201513740D0 GBGB1513740.9A GB201513740A GB201513740D0 GB 201513740 D0 GB201513740 D0 GB 201513740D0 GB 201513740 A GB201513740 A GB 201513740A GB 201513740 D0 GB201513740 D0 GB 201513740D0
Authority
GB
United Kingdom
Prior art keywords
muscarinic agonist
muscarinic
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1513740.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB1513740.9A priority Critical patent/GB201513740D0/en
Publication of GB201513740D0 publication Critical patent/GB201513740D0/en
Priority to CA2994143A priority patent/CA2994143C/en
Priority to JP2018504993A priority patent/JP6847093B2/ja
Priority to PCT/GB2016/052384 priority patent/WO2017021728A1/en
Priority to ES16750221T priority patent/ES2894855T3/es
Priority to CN201680045225.6A priority patent/CN107949384B/zh
Priority to HK18109573.6A priority patent/HK1250139B/en
Priority to US15/749,743 priority patent/US10548884B2/en
Priority to EP16750221.0A priority patent/EP3331528B1/en
Priority to AU2016302047A priority patent/AU2016302047B2/en
Priority to DK16750221.0T priority patent/DK3331528T3/da
Priority to US16/728,762 priority patent/US11324738B2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1513740.9A 2015-08-03 2015-08-03 Muscarinic agonist Ceased GB201513740D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1513740.9A GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist
DK16750221.0T DK3331528T3 (da) 2015-08-03 2016-08-03 Muskarinagonister
ES16750221T ES2894855T3 (es) 2015-08-03 2016-08-03 Agonistas muscarínicos
JP2018504993A JP6847093B2 (ja) 2015-08-03 2016-08-03 ムスカリン様アゴニスト
PCT/GB2016/052384 WO2017021728A1 (en) 2015-08-03 2016-08-03 Muscarinic agonists
CA2994143A CA2994143C (en) 2015-08-03 2016-08-03 Muscarinic agonists
CN201680045225.6A CN107949384B (zh) 2015-08-03 2016-08-03 毒蕈碱激动剂
HK18109573.6A HK1250139B (en) 2015-08-03 2016-08-03 Muscarinic agonists
US15/749,743 US10548884B2 (en) 2015-08-03 2016-08-03 Muscarinic agonists
EP16750221.0A EP3331528B1 (en) 2015-08-03 2016-08-03 Muscarinic agonists
AU2016302047A AU2016302047B2 (en) 2015-08-03 2016-08-03 Muscarinic agonists
US16/728,762 US11324738B2 (en) 2015-08-03 2019-12-27 Muscarinic agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1513740.9A GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist

Publications (1)

Publication Number Publication Date
GB201513740D0 true GB201513740D0 (en) 2015-09-16

Family

ID=54063147

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1513740.9A Ceased GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist

Country Status (10)

Country Link
US (2) US10548884B2 (enExample)
EP (1) EP3331528B1 (enExample)
JP (1) JP6847093B2 (enExample)
CN (1) CN107949384B (enExample)
AU (1) AU2016302047B2 (enExample)
CA (1) CA2994143C (enExample)
DK (1) DK3331528T3 (enExample)
ES (1) ES2894855T3 (enExample)
GB (1) GB201513740D0 (enExample)
WO (1) WO2017021728A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP7497294B2 (ja) * 2018-03-23 2024-06-10 ファイザー・インク ピペラジンアザスピロ誘導体
GB201810239D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11746107B2 (en) * 2019-09-25 2023-09-05 Molecure S.A. Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine
CN119390705A (zh) * 2019-10-09 2025-02-07 诺华股份有限公司 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
PE20221453A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
AR121260A1 (es) * 2020-02-05 2022-05-04 Neurocrine Biosciences Inc Antagonistas del receptor muscarínico 4 y métodos de uso
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025030095A1 (en) * 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643320A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
EP2344457A1 (en) 2008-10-29 2011-07-20 Grünenthal GmbH Substituted spiroamines
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
ES2619829T3 (es) * 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
AU2013319989C1 (en) * 2012-09-18 2017-08-17 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic M1 receptor agonists
WO2014122474A1 (en) * 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2015118342A1 (en) * 2014-02-06 2015-08-13 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist

Also Published As

Publication number Publication date
WO2017021728A9 (en) 2017-04-27
US10548884B2 (en) 2020-02-04
WO2017021728A1 (en) 2017-02-09
AU2016302047A1 (en) 2018-02-15
CA2994143C (en) 2023-09-26
ES2894855T3 (es) 2022-02-16
CN107949384B (zh) 2025-02-28
US11324738B2 (en) 2022-05-10
AU2016302047A8 (en) 2018-03-08
JP6847093B2 (ja) 2021-03-24
JP2018522034A (ja) 2018-08-09
US20180228791A1 (en) 2018-08-16
CA2994143A1 (en) 2017-02-09
AU2016302047B2 (en) 2020-09-10
DK3331528T3 (da) 2021-10-25
US20200129496A1 (en) 2020-04-30
HK1250139A1 (en) 2018-11-30
CN107949384A (zh) 2018-04-20
EP3331528A1 (en) 2018-06-13
EP3331528B1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
ZA201800715B (en) Muscarinic agonists
GB201513740D0 (en) Muscarinic agonist
GB201501297D0 (en) Device
GB201513743D0 (en) Muscarinic agonists
SG11201607458QA (en) Muscarinic receptor agonists
GB2537033B (en) Device
PL3328248T3 (pl) Ulepszone przesuwne pionowo urządzenie do zawieszania ubrań
GB201521136D0 (en) Device
SG11201708455YA (en) Shutoff-opening device
GB201515777D0 (en) Device
TWI562713B (en) Elcetronic device
HUE056371T2 (hu) Átömlesztõ eszköz
EP3265466A4 (en) Peripheral-anticholinergic muscarinic agonist combination
GB201519583D0 (en) Device
ZA201704941B (en) Pondage device
PL3350533T3 (pl) Urządzenie tłumiące odrzut
GB201610183D0 (en) Structure
PT3391016T (pt) Amostrador
IL237991A0 (en) Player
ZA201807587B (en) Polytunnel structure
GB201610190D0 (en) Structure
PT3075370T (pt) Dispositivo de automassagem
GB201520882D0 (en) Device
GB201520322D0 (en) Device
GB201513473D0 (en) Device

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)